Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Incyte Corporation INCY

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.


Top institutional share ownership of Incyte Corporation

Name Shares Shares % change Value Value % change
Baker Bros. Advisors Lp 36,154,574 0.0% $2,409,341 -12.3%
Vanguard Group Inc 21,228,061 1.1% $1,414,638 -11.3%
Dodge & Cox 19,793,400 -1.4% $1,319,032 -13.5%
BlackRock Inc. 19,644,663 3.1% $1,309,121 -9.6%
DODGX - Dodge & Cox Stock Fund 12,219,700 0.2% $814,321 -12.1%
Wellington Management Group Llp 10,322,426 1.7% $687,886 -10.8%
State Street Corp 9,552,953 1.1% $636,609 -11.4%
Royal Bank Of Canada 9,206,851 0.6% $613,542 -11.7%
VGHCX - Vanguard Health Care Fund Investor Shares 8,355,395 -7.2% $621,140 -11.2%
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 5,654,868 2.0% $376,840 -10.6%

Top institutional buyers of Incyte Corporation

Name Shares % change Value % change Shares Value
Amundi 344.8% 288.2% 1,798,465 $124,992
Barclays Plc 197.1% 160.6% 1,787,295 $119,106
Armistice Capital, Llc 18.3% 3.8% 2,366,000 $157,670
Invesco Ltd. 8.7% -4.6% 2,360,581 $157,311
BlackRock Inc. 3.1% -9.6% 19,644,663 $1,309,121
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 2.0% -10.6% 5,654,868 $376,840
Wellington Management Group Llp 1.7% -10.8% 10,322,426 $687,886
Vanguard Group Inc 1.1% -11.3% 21,228,061 $1,414,638
State Street Corp 1.1% -11.4% 9,552,953 $636,609
Geode Capital Management, Llc 1.0% -11.3% 3,769,861 $250,936

Top institutional sellers of Incyte Corporation

Name Shares % change Value % change Shares Value
Price T Rowe Associates Inc /md/ -32.3% -40.6% 2,306,872 $153,730
Ubs Asset Management Americas Inc -11.1% -22.0% 1,932,324 $128,770
VGHCX - Vanguard Health Care Fund Investor Shares -7.2% -11.2% 8,355,395 $621,140
Renaissance Technologies Llc -5.8% -17.3% 4,847,233 $323,020
Northern Trust Corp -3.2% -15.1% 1,934,163 $128,892
Dodge & Cox -1.4% -13.5% 19,793,400 $1,319,032
Bellevue Group AG -1.1% -13.2% 2,744,277 $182,878
FXAIX - Fidelity 500 Index Fund -0.9% 12.1% 2,001,937 $159,494
Spdr S&p 500 Etf Trust -0.6% -12.8% 2,018,539 $134,515

Information provided by Fintel.io